D. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)

Key Points

• Investment analysts at D. Boral Capital have reaffirmed a "buy" rating for Immunic (NASDAQ:IMUX) with a price objective of $10.00.
• Immunic's stock has recently dropped 7.9% and is currently trading at $0.90, with a twelve-month low of $0.56.
• The company reported earnings of ($0.20) per share, which missed analysts' expectations, and is projected to post -0.94 earnings per share for the current year.

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Several other research firms also recently weighed in on IMUX. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Immunic in a research report on Thursday, May 1st. William Blair restated an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. Finally, B. Riley reiterated a "buy" rating and issued a $5.00 price objective (down previously from $6.00) on shares of Immunic in a report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $7.50.

Immunic Stock Down 7.9%

IMUX opened at $0.90 on Friday. Immunic has a twelve month low of $0.56 and a twelve month high of $2.11. The company has a 50-day moving average price of $0.84 and a 200 day moving average price of $0.97. The company has a market cap of $86.46 million, a PE ratio of -0.73 and a beta of 1.39.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). As a group, sell-side analysts expect that Immunic will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. 683 Capital Management LLC increased its holdings in shares of Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock valued at $700,000 after purchasing an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC increased its holdings in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock worth $215,000 after buying an additional 22,200 shares during the last quarter. Focus Partners Wealth increased its holdings in shares of Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock worth $2,168,000 after buying an additional 23,610 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of Immunic during the 4th quarter worth approximately $37,000. Finally, Barclays PLC acquired a new stake in shares of Immunic during the 4th quarter worth approximately $84,000. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.